Literature DB >> 26508039

Sex-specific and race/ethnicity-specific disparities in cholangiocarcinoma incidence and prevalence in the USA: An updated analysis of the 2000-2011 Surveillance, Epidemiology and End Results registry.

Sasan Mosadeghi1, Benny Liu1, Taft Bhuket1, Robert J Wong1.   

Abstract

AIM: Cholangiocarcinoma (CCA) is an uncommon but lethal malignancy with an increasing worldwide incidence of intrahepatic cholangiocarcinoma (ICC), but decreasing incidence of extrahepatic cholangiocarcinoma (ECC). To evaluate age-specific, sex-specific, race/ethnicity-specific variations in CCA incidence in the USA.
METHODS: Using population-based cancer registry data from the 2000-2011 Surveillance, Epidemiology and End Results registry, we retrospectively evaluated age-specific, sex-specific, race/ethnicity-specific variations in incidence and prevalence of CCA stratified by ICC and ECC subtypes among adults in the USA.
RESULTS: A total of 11 296 patients with ICC and 8672 patients with ECC were identified. ICC incidence was significantly higher than ECC incidence (1.6 vs 1.3 per 100 000/year, P < 0.01). Among all race/ethnic groups and among both ICC and ECC, Asians had the highest cancer incidence. When stratified by age, CCA incidence increased with age among all groups; however, the rising incidence was most rapid among Asians. For example, among patients aged 80 years and over, the incidence of ICC among Asians was nearly twice the incidence among non-Hispanic whites (13.8 vs 7.2 per 100 000/year). Overall, CCA incidence was higher among men compared with women, and with increasing age, this sex-specific disparity was more pronounced. For example, among patients aged 80 years and over, the incidence of ICC was 9.8 per 100 000/year among men and 6.9 per 100 000/year among women.
CONCLUSION: Among adults with CCA in the USA, increasing age was associated with increasing incidence of CCA. In addition, sex-specific and race/ethnicity-specific disparities were seen with the highest incidence of CCA among men and among Asians.
© 2015 The Japan Society of Hepatology.

Entities:  

Keywords:  Surveillance, Epidemiology and End Results; cholangiocarcinoma; extrahepatic; intrahepatic; race/ethnicity

Year:  2015        PMID: 26508039     DOI: 10.1111/hepr.12605

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  16 in total

1.  Tumor grade and sex should influence the utilization of portal lymphadenectomy for early stage intrahepatic cholangiocarcinoma.

Authors:  Sean P Martin; Samantha Ruff; Laurence P Diggs; Justin Drake; Reed I Ayabe; Zachary J Brown; Michael M Wach; Seth M Steinberg; Jeremy L Davis; Jonathan M Hernandez
Journal:  HPB (Oxford)       Date:  2018-08-20       Impact factor: 3.647

2.  Urinary Metabolites Diagnostic and Prognostic of Intrahepatic Cholangiocarcinoma.

Authors:  Christopher M Diehl; Amelia L Parker; Majda Haznadar; Kristopher W Krausz; Elise D Bowman; Siritida Rabibhadana; Marshonna Forgues; Vajarabhongsa Bhudhisawasdi; Frank J Gonzalez; Chulabhorn Mahidol; Anuradha Budhu; Xin W Wang; Mathuros Ruchirawat; Curtis C Harris
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-07-29       Impact factor: 4.254

3.  Epidemiology and Risk Factors of Cholangiocarcinoma.

Authors:  Martha M Kirstein; Arndt Vogel
Journal:  Visc Med       Date:  2016-12-01

4.  Increasing mortality of intrahepatic cholangiocarcinoma in the US: are gender-specific risk factors important?

Authors:  Samuel O Antwi; Tushar Patel
Journal:  Hepatobiliary Surg Nutr       Date:  2019-12       Impact factor: 7.293

5.  Preoperative Bilirubin-Adjusted Carbohydrate Antigen 19-9 as a Prognostic Factor for Extrahepatic Cholangiocarcinoma Patients at a Single Center.

Authors:  Jiayi Li; Qiao Chen; Bao Jin; Yue Shi; Xiangan Wu; Haifeng Xu; Yongchang Zheng; Yingyi Wang; Shunda Du; Xin Lu; Yilei Mao; Xinting Sang
Journal:  Cancer Manag Res       Date:  2020-01-20       Impact factor: 3.989

6.  A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin.

Authors:  Kabir Mody; Samuel O Antwi; David O Hodge; Sikander Ailawadhi; Lewis Roberts; Tanios Bekaii-Saab
Journal:  J Gastrointest Oncol       Date:  2018-12

Review 7.  The role of 90Y-radioembolization in downstaging primary and secondary hepatic malignancies: a systematic review.

Authors:  M N G J A Braat; M Samim; M A A J van den Bosch; M G E H Lam
Journal:  Clin Transl Imaging       Date:  2016-04-23

Review 8.  Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

Authors:  Nader N Massarweh; Hashem B El-Serag
Journal:  Cancer Control       Date:  2017 Jul-Sep       Impact factor: 3.302

9.  Decreased argininosuccinate synthetase expression in Thai patients with cholangiocarcinoma and the effects of ADI-PEG20 treatment in CCA cell lines.

Authors:  Somphon Roeksomtawin; Panida Navasumrit; Somchamai Waraprasit; Varabhorn Parnlob; Thaniya Sricharunrat; Vajarabhongsa Bhudhisawasdi; Niramol Savaraj; Mathuros Ruchirawat
Journal:  Oncol Lett       Date:  2018-05-24       Impact factor: 2.967

10.  lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in cholangiocarcinoma.

Authors:  Gongcai Qiu; Donglai Ma; Fujun Li; Dongsheng Sun; Zhaolin Zeng
Journal:  Int J Oncol       Date:  2019-05-06       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.